Compounds > (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
Page last updated: 2024-08-16

(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and urb 597

(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with urb 597 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andrzejak, V; Barczyk, A; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; Leleu-Chavain, N; Millet, R; Rigo, B; Tourteau, A1
Appendino, G; Caprioglio, D; Chicca, A; Gertsch, J; Minassi, A; Petrucci, V; Taglialatela-Scafati, O1
Abbadie, C; Alexander, JP; Alvaro, R; Bakshi, RK; Belyk, KM; Chang, L; Chioda, MD; Chobanian, HR; Dellureficio, JP; DeVita, RJ; Frey, L; Fung, S; Guo, Y; Hajdu, R; Hong, Q; Jochnowitz, N; Karanam, B; Krska, SW; Lanza, TJ; Leone, JF; Lin, LS; Liu, P; Madeira, M; Makarewicz, AK; Martel, EJ; McGowan, E; McLaughlin, M; Mistry, S; Nargund, RP; Rosenbach, M; Salituro, G; Shiao, LL; Shuman, J; Sullivan, KM; Terebetski, JL; Wyvratt, MJ1
Aiello, F; Brizzi, A; Brizzi, V; Cascio, MG; Corelli, F; De Petrocellis, L; Di Marzo, V; Lamponi, S; Ligresti, A; Luongo, L; Maione, S; Marini, P; Pertwee, RG1

Other Studies

4 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and urb 597

ArticleYear
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Mar-01, Volume: 24, Issue:5

    Topics: Adamantane; Amidohydrolases; Animals; Anti-Inflammatory Agents; Body Weight; Cannabinoids; Colitis; Disease Models, Animal; Enzyme Inhibitors; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB2; Structure-Activity Relationship

2014
Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system.
    ACS chemical biology, 2014, Jul-18, Volume: 9, Issue:7

    Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; CHO Cells; Cricetulus; Cyclooxygenase 2 Inhibitors; Endocannabinoids; Humans; Polycyclic Sesquiterpenes; Polypharmacology; Receptor, Cannabinoid, CB2; Sesquiterpenes; Syzygium

2014
Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.
    ACS medicinal chemistry letters, 2014, Jun-12, Volume: 5, Issue:6

    Topics:

2014
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
    Bioorganic & medicinal chemistry, 2014, Sep-01, Volume: 22, Issue:17

    Topics: Analgesics; Animals; Calcium Channels; Cell Survival; Cells, Cultured; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Humans; Ligands; Male; Mice; Molecular Structure; Nerve Tissue Proteins; NIH 3T3 Cells; Nociception; Pain; Pain Measurement; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Resorcinols; Structure-Activity Relationship; Transient Receptor Potential Channels; TRPA1 Cation Channel

2014